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Abstract. The iridium-catalyzed asymmetric 
hydrogenation of several N-sulfonyl allyl amines is 
reported. All substrates can be easily obtained by the Ir-
catalyzed isomerization of N-tosylaziridines reported 
previously. The commercially available threonine-derived 
phosphinite (UbaPHOX) iridium complex has been found 
to be the best catalyst for this catalytic application, 
affording β-methyl amines with good to excellent ee values 
(up to 94%). The synthetic potential of this novel 
methodology was demonstrated by the formal synthesis of 
Lorcaserin and LY-404187. 
Keywords: iridium complexes; asymmetric catalysis; 
hydrogenation; β-alkyl amines; Drug synthesis; Chiral 
P,N-ligands 
Chiral amines are key structural features in natural 
products and fine chemicals.[1,2] Amines bearing a β-
methyl stereogenic center are present in numerous 
bioactive compounds and pharmaceuticals.[3-5] Several 
examples of this type of drugs are shown in Figure 1. 
For example, Lorcaserin is a marketed anorectic for 
which a synthesis based on asymmetric hydrogenation 
have not been described to date.[3] 
Biarylpropylsulfonamides such as LY-404187 are 
potent positive allosteric modulators of 2-amino-3-(5-
methyl-3-hydroxyisoxazol-4-yl)-propanoic acid 
(AMPA) receptors.[4] NPS-1392 is a potent 
stereoselective antagonist of the NMDA receptor.[5]  
The asymmetric hydrogenation is one of the most 
important catalytic reactions in the preparation of 
pharmaceuticals due to its atom economy, low 
environmental impact and operational simplicity.[6] Ru 
or Rh catalysts, which usually bear chiral phosphines, 
can induce high enantioselectivity on substrates 
functionalized with a coordinating group.[7] However, 
when facing minimally functionalized olefins, these 
catalysts commonly show low reactivity and 
asymmetric induction. Conversely, Ir complexes 
bearing chiral P,N-ligands[8] can be used in the 
hydrogenation of poorly coordinative alkenes. 
Although several minimally functionalized olefins 
have been enantioselectively hydrogenated with Ir 
complexes,[9] the range of substrates available is still 
limited. In this context, reports of the asymmetric 
synthesis of β-methyl amines from 2-aryl allylamines 
are scarce. Zhang and co-workers developed a highly 
enantioselective method for the synthesis of β-methyl 
phthalimides based on the asymmetric hydrogenation 
of 2-alkyl allylphthalimides using a Ru-C3-tunephos 
catalyst.[10] However, hydrogenation of the only 
example of 2-aryl allylphthalimide described in the 
paper took place with low enantiomeric excess (55% 
ee). The hydrogenation of N-acetamido 2-phenyl 
allylamine using a cationic Ru complex bearing the 
axially chiral ligand (-)-TMBTP gave an ee of 80%.[11] 
However, in this case, the hydrogenation occurred 
after partial isomerization to the enamide. Therefore, 
to the best of our knowledge, there are no precedents 
of Ir-catalyzed asymmetric hydrogenation of N-
sulfonyl 2-aryl allylamines.  
 
Figure 1. Examples of pharmaceutically active chiral β-
methyl amines. 
 2 
In theory, all compounds shown in Figure 1 can be 
prepared by asymmetric hydrogenation of a suitable 
allyl amine. However, the absence of appropriate 
methodologies might be explained by the lack of easy 
preparation procedures for 2-aryl allylamines. Our 
group recently uncovered a new isomerization reaction 
that provides N-sulfonyl 2-aryl allylamines 2 from N-
sulfonyl aziridines 1 (Scheme 1).[12] The isomerization 
is catalyzed by the readily available Crabtree catalyst 
and takes place with low catalyst loading, high 
selectivity and mild reaction conditions.  
Herein, we report the Ir-catalyzed asymmetric 
hydrogenation of N-sulfonyl allylic amines 2 to chiral 
β-methyl amines 3 (Scheme 1; 16 examples). The 
commercial iridium-UbaPhox catalyst[13] developed 
by Pfaltz gave complete conversions and good to 
excellent enantioselectivities. The high functional 
group tolerance and the mild conditions employed in 
this novel catalytic process are remarkable. To 
showcase the applicability of this new enantioselective 
methodology, the asymmetric synthesis of several 
biologically active compounds is also described. 
Scheme. 1. Synthetic approach to chiral β-
methylamines 
Our studies first began with the asymmetric 
hydrogenation of 2a, which was chosen as model 
substrate (Table 1). This compound was easily 
obtained by isomerization of the corresponding N-
tosyl aziridine which, in turn was prepared from 1-
methylstyrene. With 2a in hand, several Rh- and Ir-
catalysts were tested for their asymmetric 
hydrogenation. However, the best results were 
obtained using [((4S,5S)-Cy2-Ubaphox)Ir(COD)] 
BArF (4), the threonine-based Ir-P,N catalysts 
developed by Pfaltz.[13] The optimization of the 
reaction conditions is shown in Table 1. Methanol 
gave low conversion (Table 1, entry 1). Ethers such as 
THF, dioxane and diethyl ether gave complete 
conversions but moderate ee values (Table 1, entries 
2-4). Ethyl acetate and dichloromethane gave better 
results, but dichloroethane (DCE) (Table 1, entry 7,) 
emerged as the best solvent for the reaction, with full 
conversion and 93% ee. A decrease in the temperature 
of the reaction (Table 1, entry 8) or an increase of 
hydrogen pressure (Table 1, entry 9) had a small effect 
in the asymmetric induction. Finally, the reaction was 
achieved with 1 mol % of catalyst loading and 1 bar of 
hydrogen (Table 1, entry 10). Under these conditions 
the reaction reached completion in only 3 h.  
We also tested the one pot procedure treating aziridine 
1a with hydrogen (1-50 bar) in the presence of catalyst 
4 (see SI). Although the N-tosyl 2-phenylpropanamine 
3a was obtained cleanly, the maximum enantiomeric 
excess that we could obtain was 83% ee. We believe 
that this was due to the uncomplete selectivity of the 
isomerization reaction. The presence of 3-7% of 
racemic imine drops the enantioselectivity of the 
overall reaction.  
Table 1. Solvent screening and optimization of the 











1 5 MeOH 1 bar, rt 30 75 (R) 
2 5 THF 1 bar, rt >99 82 (R) 
3 5 dioxane 1 bar, rt >99 76 (R) 
4 5 Et2O 1 bar, rt >99 74 (R) 
5 5 EtOAc 1 bar, rt >99 83 (R) 
6 5 CH2Cl2 1 bar, rt >99 88 (R) 
7 5 DCE 1 bar, rt >99 93 (R) 
8 5 DCE 1 bar, 0ºC >99 93 (R) 
9 5 DCE 50 bar, rt >99 91 (R) 
10d 1 DCE 1 bar, rt >99 93 (R) 
a See Supporting Information for experimental details. Reactions were run in 
a pressure reactor at 1 bar of H2 pressure. b Conversion was measured by 1H 
NMR. c Enantiomeric excess was determined by chiral HPLC. d The reaction 
was completed after 3 h. 
To determine the scope of the reaction, we next 
applied these optimal conditions to a range of N-
sulfonyl allylic amines. Up to 15 N-sulfonyl allylic 
amines were tested showing excellent reactivity and 
affording the chiral amines in high conversions and 
with good to excellent ee values (Table 2). We 
assumed that all products had R configuration by 
analogy with 3a. The absolute configuration of 3a had 
been stablished by derivatization of ethyl (R)-2-
phenylpropanoate.[14] In all cases, except 2d-e, the sign 
of the rotation matched with 3a. We believe that in all 
cases the sense of the induction is the same. Substrates 
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presenting substituents in ortho position (Table 2, 
entries 3 and 6) and naphthalene (Table 2, entry 5) 
required an increase in catalyst loading (2 mol %) to 
assure full conversion. This novel catalytic 
transformation demonstrated high functional group 
tolerance when modifying the electronic character 
(electron-donor and electron-withdrawing 
substituents) in the aryl group. The sulfonyl group was 
also modified and we were pleased to see that when 
replacing the tosyl group by a methyl or isopropyl 
group, full conversion and excellent ee’s were also 
achieved (Table 2, entries 10, 11, 12 and 13). Finally, 
N-methyl, N-sulfonyl allylic amines 2o and 2p were 
also hydrogenated affording the corresponding chiral 
amines with 94% of enantiomeric excess in both cases 
(Table 2, entries 14 and 15).  
To check if the hydrogenation takes place after 
isomerization to the corresponding enamide, labeling 
studies were conducted. Allyl amine 2a was 
hydrogenated with 1 bar of D2 and 1 mol % of 4 in 
DCE. NMR analysis showed that the deuterium atoms 
were exclusively found at the methyl and benzylic 
positions. Therefore, the possible isomerization 
previous to hydrogenation was ruled out (see SI). 
Table 2. Scope of Asymmetric Hydrogenation of N-
Sulfonyl Allyl Amines 
 





1 2b p-Cl p-tolyl H >99 85 
2 2c m-Cl p-tolyl H >99 89 
3d 2d o-Cl p-tolyl H >99 82 
4 2e p-Me p-tolyl H >99 92 
5d 2f 2-naphthyl p-tolyl H >99 88 
6d 2g o-OMe p-tolyl H >99 92 
7 2h p-F p-tolyl H >99 91 
8 2i m-F p-tolyl H >99 92 
9 2j p-CF3 p-tolyl H >99 82 
10 2k p-Br iPr H >99 87 
11 2l p-I iPr H >99 88 
12 2m H Me H >99 92 
13 2n p-iBu Me H >99 91 
14 2o H Me Me >99 94 
15 2p H p-tolyl Me >99 94 
a All reactions were run in a pressure reactor at 1 bar of H2 pressure. b 
Conversion was measured by 1H NMR. c Enantiomeric ratio was determined 
by chiral HPLC. d 2 mol% of catalyst was used. 
Many biologically active compounds have amines 
with a chiral methyl group in -position. Compound 
2a is already a direct precursor of potassium channel 
inhibitors after simple tosyl deprotection and acylation 
[15,16] (see SI). The mesyl amine 2m is also a key 
intermediate for the preparation of allosteric 
modulators of AMPA receptor.[16,17] However, to 
further showcase the applicability of our methodology, 
and encouraged by the relevance of these chiral β-
methyl amines as fragments of biologically active 
compounds we envisioned easy access to LY-404187 
and (R)-Lorcaserin. To obtain the 
biarylpropylsulfonamide LY-404187,[4] we designed a 
3-step synthetic procedure starting from N-sulfonyl 
aziridine 1l. The isomerization[12] of 1l to 2l and the 
subsequent asymmetric hydrogenation to 3l took place 
in excellent yields. Finally, the chiral amine 3l was 
converted to the final product by a Suzuki-Miyaura 
coupling. LY-404187, the potent potentiator of the 
AMPA receptor, was obtained as the only product with 
good yield and almost no loss of optical purity 
(Scheme 2).  
 
Scheme 2. Synthesis of LY-404187  
The anorectic drug Lorcaserin has a tetrahydro-3-
benzazepine skeleton, a common structural feature in 
many natural and pharmaceutical products. Lorcaserin 
has serotonergic properties and is currently used as a 
weight-loss drug. Several racemic syntheses of this 
compound have been reported. Only a few strategies 
for the enantioenriched form of this drug can be found 
in the literature, and most of them use kinetic 
resolution or stoichiometric reagents.[18] We 
envisioned to apply our novel catalytic asymmetric 
methodology (Scheme 3). N-sulfonyl aziridine 1c was 
isomerized[12] and the corresponding allyl amine was 
hydrogenated to afford 3c in good yield and 89% ee. 
Subsequent N-alkylation gave 5 in 68% yield. 
Regioselective Lewis acid-promoted intramolecular 
Friedel-Craft alkylation[3b] afforded the unsaturated 7-
membered ring. Finally, enamine hydrogenation gave 




Scheme 3. Formal synthesis of (R)-Lorcaserin. 
In summary, we have shown that commercially 
available complex Ir(UbaPHOX) (4) is an excellent 
catalyst for the challenging asymmetric hydrogenation 
of 2-aryl N-sulfonyl allylamines. The hydrogenation 
takes place at low hydrogen pressure (1 bar) and with 
only 1 mol % of catalyst in DCE at room temperature. 
Since the starting amines can be easily obtained by Ir-
catalyzed isomerization of N-tosylaziridines, which in 
turn can be prepared from the corresponding styrenes, 
the overall sequence provides a straightforward and 
practical route to chiral amines bearing a methyl group 
in β position. These compounds are useful synthetic 
intermediates since they are, or can be transformed 
into, precursors of several biologically active 
compounds. As a synthetic application of this 
methodology, we have described the formal synthesis 
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